Statement of Changes in Beneficial Ownership (4)
May 03 2021 - 7:00PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Taylor Stacy L |
2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp
[
ADPT
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) SVP and General Counsel |
(Last)
(First)
(Middle)
C/O ADAPTIVE BIOTECHNOLOGIES, 1551 EASTLAKE AVE E STE 200 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
4/30/2021 |
(Street)
SEATTLE, WA 98102
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 4/30/2021 | | M(1) | | 1042 | A | $7.80 | 16078 | D | |
Common Stock | 4/30/2021 | | M(1) | | 1770 | A | $6.55 | 17848 | D | |
Common Stock | 4/30/2021 | | M(1) | | 1354 | A | $31.71 | 19202 | D | |
Common Stock | 4/30/2021 | | S(1) | | 4166 | D | $41.93 (2) | 15036 | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock Option (Right to Buy) | $7.80 | 4/30/2021 | | M (1) | | | 1042 | (3) | 4/23/2029 | Common Stock | 1042 | $0.00 | 25000 | D | |
Stock Option (Right to Buy) | $6.55 | 4/30/2021 | | M (1) | | | 1770 | (4) | 4/24/2028 | Common Stock | 1770 | $0.00 | 19480 | D | |
Stock Option (Right to Buy) | $31.71 | 4/30/2021 | | M (1) | | | 1354 | (5) | 2/13/2030 | Common Stock | 1354 | $0.00 | 46042 | D | |
Explanation of Responses: |
(1) | The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 23, 2020. |
(2) | The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $41.68 to 42.14, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4. |
(3) | The options vested with respect to 1/4 of such shares on April 23, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
(4) | The options vested with respect to 1/4 of such shares on March 12, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
(5) | The options vested with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Taylor Stacy L C/O ADAPTIVE BIOTECHNOLOGIES 1551 EASTLAKE AVE E STE 200 SEATTLE, WA 98102 |
|
| SVP and General Counsel |
|
Signatures
|
/s/ Stacy L. Taylor by Eric Billings as attorney-in-fact | | 5/3/2021 |
**Signature of Reporting Person | Date |
Adaptive Biotechnologies (NASDAQ:ADPT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adaptive Biotechnologies (NASDAQ:ADPT)
Historical Stock Chart
From Sep 2023 to Sep 2024